Lack of Susceptibility of Bicyclic Nucleoside Analogs, Highly Potent Inhibitors of Varicella-Zoster Virus, to the Catabolic Action of Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase
- 1 May 2002
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 61 (5) , 1140-1145
- https://doi.org/10.1124/mol.61.5.1140
Abstract
The susceptibility of the bicyclic nucleoside analogs (BCNAs), highly potent and selective inhibitors of varicella-zoster virus (VZV), to the enzymes involved in nucleoside/nucleobase catabolism has been investigated in comparison with the established anti-VZV agent (E)-5-(2-bromovinyl)-2′-deoxyuridine [BVDU; brivudine (Zostex)]. Whereas human and bacterial thymidine phosphorylases (TPases) efficiently converted BVDU to its antivirally inactive free base (E)-5-(2-bromovinyl)uracil (BVU), BCNAs showed no evidence of conversion to the free base in the presence of these enzymes. The lack of substrate affinity of TPase for the BCNAs could be rationalized by computer-assisted molecular modeling of the BCNAs in the TPase active site. Moreover, in contrast with BVU, which is a potent and selective inhibitor of dihydropyrimidine dehydrogenase (DPD) (50% inhibitory concentration; 10 μM in the presence of a 25 μM concentration of the natural substrate thymine), the free base (Cf 1381; 6-octyl-2,3-dihydrofuro[2,3-d]pyrimidin-2-one) of BCNA (Cf 1368; 3-(2′-deoxy-β-d-ribofuranosyl)-6-octyl-2,3-dihydrofuro[2,3-d]pyrimidin-2-one) and the free base Cf 2200 [6-(4-n-pentylphenyl)-2,3-dihydrofuro[2,3-d]pyrimidin-2-one] of BCNA (Cf 1743; 3-(2′-deoxy-β-d-ribofuranosyl)-6-(4-n-pentylphenyl)-2,3-dihydrofuro[2,3-d]pyrimidin-2-one) did not inhibit the DPD-catalyzed catabolic reaction of pyrimidine bases (i.e., thymine) and pyrimidine base analogs [i.e., 5-fluorouracil (FU)] at a concentration of 250 μM. Consequently, whereas BVU caused a dramatic rise of FU levels in FU-treated mice, the BCNAs did not affect FU levels in such mice. From our data it is evident that BCNAs represent highly stable anti-VZV compounds that are not susceptible to breakdown by nucleoside/nucleobase catabolic enzymes and are not expected to interfere with cellular catabolic processes such as those involved in FU catabolism.Keywords
This publication has 19 references indexed in Scilit:
- Bicyclic pyrimidine nucleoside analogues (BCNAs) as highly selective and potent inhibitors of varicella-zoster virus replicationJournal of Antimicrobial Chemotherapy, 2002
- Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosidesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2002
- Antiviral Activity of Nucleoside Analogues: The BVDU ConnectionPublished by Elsevier ,2002
- Highly Potent and Selective Inhibition of Varicella-Zoster Virus by Bicyclic Furopyrimidine Nucleosides Bearing an Aryl Side ChainJournal of Medicinal Chemistry, 2000
- Further additions to MolScript version 1.4, including reading and contouring of electron-density mapsActa Crystallographica Section D-Biological Crystallography, 1999
- Sorivudine and 5‐fluorouracil; a clinically significant drug‐drug interaction due to inhibition of dihydropyrimidine dehydrogenaseBritish Journal of Clinical Pharmacology, 1998
- Regeneration of the antivirel drug(E)-5-(2-bromovinyl)-2′ -deoxyuridinein vivoNucleic Acids Research, 1984
- The antiviral spectrum of (E)-5-(2-bromovinyl)-2 '-deoxyuridineJournal of Antimicrobial Chemotherapy, 1984
- Phosphorolysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and other 5-substituted-2'-deoxyuridines by purified human thymidine phosphorylase and intact blood plateletsBiochemical Pharmacology, 1983
- (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent.Proceedings of the National Academy of Sciences, 1979